Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Income from Continuing Operations (2017 - 2025)

Aclaris Therapeutics has reported Income from Continuing Operations over the past 9 years, most recently at 21100000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 21100000.0 for Q4 2025, up 78.37% from a year ago — trailing twelve months through Dec 2025 was 68738000.0 (up 48.69% YoY), and the annual figure for FY2025 was 68738000.0, up 47.95%.
  • Income from Continuing Operations for Q4 2025 was 21100000.0 at Aclaris Therapeutics, down from 15330000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for ACRS hit a ceiling of 1858000.0 in Q4 2023 and a floor of 97572000.0 in Q4 2024.
  • Median Income from Continuing Operations over the past 5 years was 20584500.0 (2021), compared with a mean of 23757300.0.
  • Biggest five-year swings in Income from Continuing Operations: skyrocketed 93.61% in 2023 and later plummeted 5151.45% in 2024.
  • Aclaris Therapeutics' Income from Continuing Operations stood at 22893000.0 in 2021, then dropped by 27.02% to 29079000.0 in 2022, then skyrocketed by 93.61% to 1858000.0 in 2023, then plummeted by 5151.45% to 97572000.0 in 2024, then soared by 78.37% to 21100000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 21100000.0 (Q4 2025), 15330000.0 (Q3 2025), and 16390000.0 (Q2 2025) per Business Quant data.